Hyaluronidase and other Extracellular Matrix Degrading Enzymes for Cancer Therapy: New Uses and Nano-FormulationsPablo Scodeller*
Sanford-Burnham Medical Research Institute, San Diego, USA
- *Corresponding Author:
- Pablo Scodeller
Sanford-Burnham Medical Research Institute
10901 North Torrey Pines Rd
La Jolla, CA 92037, USA
Email: [email protected]
Received date: April 04, 2014; Accepted date: April 26, 2014; Published date: May 7, 2014
Citation: Scodeller P (2014) Hyaluronidase and other Extracellular Matrix Degrading Enzymes for Cancer Therapy: New Uses and Nano- Formulations . J Carcinog Mutage 5:178. doi: 10.4172/2157-2518.1000178
Copyright: © 2014 Scodeller P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Overexpression of extracellular matrix components in tumor stroma like Hyaluronan and collagen pose a hurdle for cancer therapies. Many tumors overexpress Hyaluronic acid (HA), and Collagen. The overexpression of these components results in the elevation of a parameter called interstitial fluid pressure, which represents the resistance to the flow of a liquid. High molecular weight HA and Collagen bind water very tightly, and thus "wetting" these tumors with the drug-containing solution is impeded because it demands the displacement of those tightly bound water molecules solvating these polymers. When using conventional chemotherapy to treat a tumor, the penetration of the drug to the tissue is impoverished due to this phenomenon. This review will collect new experimental approaches for degrading the extracellular matrix with enzymes, and the use of this as an adjuvant for conventional cancer drugs. Adjuvant systems composed of free enzyme in solution or immobilized enzyme on the surface of nanoparticles or expressed by a viral vector will be dealt with.